Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
High expression of CDK6 confers resistance to fulvestrant in breast cancer cells and is a potential predictor of fulvestrant treatment failure in estrogen receptor-positive breast cancer Carla M. L. Alves1*, Daniel Elias1*, Maria Lyng1, Martin Bak2, Anne E. Lykkesfeldt3, Henrik J. Ditzel1,4* 1 Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, J. B. Winsløws Vej 25, 5000 Odense C, Denmark 2 Department of Pathology, University of Southern Denmark, J. B. Winsløws Vej 25, 5000 Odense C, Denmark 3 Breast Cancer Group, Cell Death and Metabolism, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark 4 Department of Oncology, Odense University Hospital, Søndre Boulevard 29, 5000, Odense, Denmark Estrogen receptor positive (ER+) breast cancer accounts for over 80% of breast cancers and these patients are eligible for endocrine therapy. Despite the efficacy of endocrine treatment many patients experience recurrence or disease progression as a result of resistance. To overcome or prevent endocrine resistance, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are currently being investigated in multiple clinical trials in combination with endocrine treatment in advanced breast cancer, however the role of CDK4/6 in the mechanisms of endocrine resistance remains to be defined. To explore the molecular mechanisms of fulvestrant-resistance in ER+ breast cancer, we performed gene expression array analysis of a MCF7-based fulvestrant-resistant cell line model and found that CDK6 was highly expressed in four fulvestrant-resistant cell lines vs. parental fulvestrant-sensitive cells. Higher CDK6 expression was also observed in tamoxifen and aromatase inhibitorresistant vs. parental MCF7 cells, but to much lesser extent. Reduction of CDK6 expression in all four fulvestrant-resistant cell lines using small interfering RNA restored fulvestrant sensitivity. Moreover, treatment of fulvestrant-resistant cell lines with different chemical inhibitors of CDK4/6 reduced resistance to fulvestrant. Cell cycle analysis following reduction of CDK6 in fulvestrant-resistant cells showed an increased percentage of cells in the G0/G1 phase and altered phosphorylation of retinoblastoma protein, demonstrating the growth-promoting function of CDK6 through regulation of cell cycle progression. Evaluation of CDK6 expression in metastases of ER+ breast cancer patients treated with fulvestrant in the advanced setting (N=45) showed that high expression of CDK6 was significantly associated with shorter progression-free survival (p=0.003), while no significant association between CDK6 expression and progression-free survival was observed in metastases of patients treated with the other anti-estrogen drugs, tamoxifen and aromatase inhibitors (N=41, p=0.652). Taken together, our results indicate that up-regulation of CDK6 may be important in conferring fulvestrant-resistance in breast cancer cells, and that ER+ metastatic breast tumors with high expression of CDK6 may not benefit from fulvestrant treatment alone and should be considered for additional targeted therapy with CDK4/6 inhibitors.